Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase

Active, not recruiting
Phase 2

Conditions

Childhood Cancer
Multiple Diseases

Treatments

Biological: Immunization Schedule patients > or = to 11 years of age
Biological: Immunization Schedule patients > or = to 7 years and <11 years of age
Biological: Immunization Schedule patients <7 years.

Study type

Interventional

Funder types

Other

Identifiers

NCT00505063
07-088

Details and patient eligibility

About

This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.

Enrollment

75 estimated patients

Sex

All

Ages

2 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient must be < or less 18 years of age at cancer diagnosis

Patient must be 3 to 24months following completion of chemotherapy for malignant disease.

  • For patients <12 months following completion of therapy, CR must be documented within 3 months of enrollment.
  • For patients >12 months, CR must be documented at approximately 12 months and then only as clinically indicated

i. For patients with leukemia: bone marrow aspirate defined as <5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable) and no evidence of CSF involvement (if applicable) ii. For patients with solid tumors remission will be determined by appropriate radiologic scans, and other tests, including bone marrow aspirate and biopsies demonstrating absence of extrinsic cells and absence of specific FISH or cytogenetic abnormality (if applicable), iii. For patients with lymphoma, remission will be determined by bone marrow aspirate and biopsy, radiologic scans and other tests. Bone marrow will show <5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable), and flow cytometry (if lymphoma specific marker present) and absence of CNS disease by spinal fluid (if applicable)

  • Patient may be of either gender and of any ethnic background
  • Patients or their guardians must be able to understand the nature and risk of the proposed study and be able to sign consent.

Exclusion criteria

  • Karnofsky score <70%.
  • Female patients who are pregnant or lactating.
  • Patients who have received an autologous or allogeneic HCT.
  • Active uncontrolled bacterial or fungal infection.
  • Patients who have a history of previous allergic reaction to vaccinations currently recommended by the ACIP.
  • Patients on any immunosuppressive drugs.
  • HIV-1,2 sero-positive patients.
  • Patients or guardians not signing informed consent.
  • Patients with prior allergic reaction to any vaccine component or to latex.
  • Patients who have received Rituximab.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

75 participants in 3 patient groups

A
Other group
Description:
Immunization Schedule patients <7 years.
Treatment:
Biological: Immunization Schedule patients <7 years.
B
Other group
Description:
Immunization Schedule patients > or = to 7 years and <11 years of age
Treatment:
Biological: Immunization Schedule patients > or = to 7 years and <11 years of age
C
Other group
Description:
Immunization Schedule patients > or = to 11 years of age
Treatment:
Biological: Immunization Schedule patients > or = to 11 years of age

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems